Progyny (NASDAQ:PGNY) CFO Mark Livingston Sells 8,275 Shares

Progyny, Inc. (NASDAQ:PGNY) CFO Mark Livingston sold 8,275 shares of the stock in a transaction that occurred on Wednesday, May 20th. The shares were sold at an average price of $25.50, for a total value of $211,012.50. Following the sale, the chief financial officer owned 79,063 shares of the company’s stock, valued at approximately $2,016,106.50. The trade was a 9.47% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Progyny Stock Down 3.7%

Shares of NASDAQ PGNY opened at $24.69 on Friday. The business’s 50 day moving average is $18.92 and its two-hundred day moving average is $22.01. The company has a market cap of $1.93 billion, a P/E ratio of 32.06, a P/E/G ratio of 1.36 and a beta of 0.91. Progyny, Inc. has a 12 month low of $16.10 and a 12 month high of $28.75.

Progyny (NASDAQ:PGNY) last posted its quarterly earnings data on Thursday, May 7th. The company reported $0.29 earnings per share for the quarter, beating the consensus estimate of $0.26 by $0.03. Progyny had a return on equity of 13.34% and a net margin of 5.23%.The company had revenue of $328.50 million during the quarter, compared to analysts’ expectations of $326.47 million. During the same period in the prior year, the business earned $0.17 earnings per share. Progyny’s revenue for the quarter was down 26.4% compared to the same quarter last year. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. Sell-side analysts expect that Progyny, Inc. will post 1.12 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

PGNY has been the topic of several recent research reports. Truist Financial lifted their price objective on Progyny from $28.00 to $30.00 and gave the stock a “buy” rating in a report on Monday, May 11th. Wall Street Zen upgraded Progyny from a “hold” rating to a “buy” rating in a research note on Saturday, April 18th. Citigroup reaffirmed an “outperform” rating on shares of Progyny in a research report on Monday, May 11th. Citizens Jmp lifted their price target on shares of Progyny from $30.00 to $31.00 and gave the stock a “market outperform” rating in a research note on Monday, May 11th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Progyny in a report on Friday, March 27th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $29.55.

Hedge Funds Weigh In On Progyny

A number of hedge funds have recently modified their holdings of PGNY. Wellington Management Group LLP lifted its position in shares of Progyny by 260.9% during the 4th quarter. Wellington Management Group LLP now owns 2,243,268 shares of the company’s stock worth $57,607,000 after buying an additional 1,621,688 shares during the period. Fort Washington Investment Advisors Inc. OH grew its position in Progyny by 46.9% in the first quarter. Fort Washington Investment Advisors Inc. OH now owns 2,693,393 shares of the company’s stock valued at $45,734,000 after acquiring an additional 859,289 shares during the period. Loomis Sayles & Co. L P acquired a new position in Progyny during the fourth quarter worth $19,917,000. Barclays PLC raised its stake in Progyny by 79.2% during the third quarter. Barclays PLC now owns 1,575,470 shares of the company’s stock worth $33,904,000 after acquiring an additional 696,447 shares in the last quarter. Finally, Ameriprise Financial Inc. lifted its holdings in shares of Progyny by 37.6% during the second quarter. Ameriprise Financial Inc. now owns 1,996,957 shares of the company’s stock valued at $43,933,000 after acquiring an additional 545,431 shares during the period. 94.93% of the stock is owned by institutional investors and hedge funds.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.